69 episodes
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast PeerView
-
- Science
-
-
3.6 • 5 Ratings
-
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
-
Oliver Sartor, MD - On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/QSV865. CME credit will be available until May 23, 2025.
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Blue Earth Diagnostics, Lantheus Medical Imaging, and Novartis Pharmaceuticals Corporation.
Disclosure information is available at the beginning of the video presentation. -
Jonathan A. Bernstein, MD - Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic Urticaria
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FTH865. CME credit will be available until May 5, 2025.
Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic Urticaria
The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Disclosure information is available at the beginning of the video presentation. -
Jonathan A. Bernstein, MD - BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WQU865. CME credit will be available until May 6, 2025.
BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Disclosure information is available at the beginning of the video presentation. -
Saakshi Khattri, MBBS, MD, FAAD, FACR - Interdisciplinary Approaches to Management of Immune-Mediated Inflammatory Diseases: Addressing Shared Pathophysiology With JAK Inhibitors
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/VEX865. CME/AAPA credit will be available until April 24, 2025.
Interdisciplinary Approaches to Management of Immune-Mediated Inflammatory Diseases: Addressing Shared Pathophysiology With JAK Inhibitors
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Crohn's and Colitis Foundation, National Eczema Association, and Spondylitis Association of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from AbbVie.
Disclosure information is available at the beginning of the video presentation. -
Carlos G. Romo, MD, Aimee Sato, MD - Precision and Progress Against NF1: Solutions for Better Outcomes With MEKi and Multimodal Care for NF1 pNF and Other Tumors
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025.
Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Alexion Pharmaceuticals.
Disclosure information is available at the beginning of the video presentation. -
Olalekan Oluwole, MBBS, MPH - Democratizing the CAR-T Experience: The Principles and Practice of Outpatient Cellular Therapy
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/HKJ865. CME/NCPD credit will be available until April 15, 2025.
Democratizing the CAR-T Experience: The Principles and Practice of Outpatient Cellular Therapy
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Novartis Pharmaceuticals Corporation.
Disclosure information is available at the beginning of the video presentation.